Company news

PTC Therapeutics, Inc. news in 2022

PTC Therapeutics, Inc.'s news releases, calls and decks from 2022, newest first.

View company

Brazilian Regulatory Authority Grants Approval for Waylivra™ for Familial Partial Lipodystrophy

November 30, 2022

Upstaza™ Gene Therapy Granted Marketing Authorization for AADC deficiency by UK's MHRA

November 16, 2022

PTC Therapeutics Provides a Corporate Update and Reports Third Quarter Financial Results

October 26, 2022

PTC Therapeutics Announces Strategic Financing Collaboration with Blackstone with up to $1 Billion in Funding

October 26, 2022

PTC Provides Update on Ongoing Global PIVOT-HD Trial For PTC518

October 17, 2022

PTC Therapeutics to Host Conference Call to Discuss Third Quarter 2022 Financial Results

October 12, 2022

PTC Therapeutics to Present Clinical and Real-World Evidence on Translarna™ at the Annual Congress of the World Muscle Society

October 10, 2022

PTC Therapeutics' 2022 STRIVE Awards Program Funds Initiatives Supporting the Duchenne Patient Community

September 6, 2022

PTC Therapeutics Provides a Corporate Update and Reports Second Quarter Financial Results

August 3, 2022

PTC Therapeutics to Host Conference Call to Discuss Second Quarter 2022 Financial Results

July 20, 2022

Upstaza™ Granted Marketing Authorization by European Commission as First Disease-Modifying Treatment for AADC Deficiency

July 19, 2022

PTC Therapeutics to Host Call to Review Topline Results from Study 041 for Translarna™ (ataluren) in Nonsense Mutation Duchenne Muscular Dystrophy

June 19, 2022

Biotech Investment Veteran Alethia Young Joins PTC Therapeutics' Board of Directors

June 8, 2022

PTC Therapeutics to Participate at William Blair 42nd Annual Growth Stock Conference

June 5, 2022

Preliminary Results Presented at ASCO Demonstrated Promising Clinical Efficacy with Unesbulin in Leiomyosarcoma Study

June 2, 2022

FDA Approves Label Extension for Evrysdi® for Infants with Spinal Muscular Atrophy Under 2 Months Old

May 30, 2022

PTC Therapeutics Receives Positive CHMP Opinion for Upstaza™ for the Treatment of AADC Deficiency

May 19, 2022

PTC Therapeutics to Host Conference Call to Discuss First Quarter 2022 Financial Results

April 18, 2022

PTC Therapeutics Provides Update on EMA Regulatory Review Timeline For Its AADC Deficiency Gene Therapy Program

April 13, 2022

PTC Therapeutics Announces Initiation of PIVOT-HD Phase 2 Clinical Trial to Evaluate PTC518 in Patients with Huntington's Disease

March 29, 2022

PTC Therapeutics to Present New Data at the 2022 Muscular Dystrophy Association Clinical & Scientific Conference

March 10, 2022

PTC Therapeutics Provides a Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results

February 21, 2022

PTC Therapeutics to Host Conference Call to Discuss Fourth Quarter and Year-End 2021 Financial Results

February 7, 2022

FDA Grants Evrysdi® Priority Review Based on Results From Treating Pre-Symptomatic Infants with Spinal Muscular Atrophy

January 24, 2022

PTC Therapeutics Announces Launch of 8th Annual STRIVE™ Awards Program to Fund Initiatives Benefitting the Duchenne Muscular Dystrophy Community

January 17, 2022

PTC Therapeutics Announces Launch of 2022 Global Talent Pipeline Program

January 12, 2022

PTC Therapeutics Provides an Update on Commercial Progress and R&D Pipeline at 40th Annual J.P. Morgan Healthcare Conference

January 9, 2022

Waylivra™ Receives Innovative Drug Category Pricing to Treat Familial Chylomicronemia Syndrome in Brazil

January 3, 2022

PTC Therapeutics to Present at the 40th Annual J.P. Morgan Virtual Healthcare Conference

January 2, 2022

Calls in 2022

Decks in 2022